Inhalation Sciences receives positive feedback from FDA, moves onto next stage of process to validate DissolvIt as FDA-recommended standard research method in US
(Stockholm, 5 May 2022) Inhalation Sciences (ISAB) has received positive feedback from the US FDA (Food and Drug Administration) on its white paper, previously communicated on 17 January 2022, that aims to validate the company’s DissolvIt[®] model as an FDA-recommended technology. ISAB has now been invited to submit a full proposal for its research project into DissolvIt[®]. If successful, the FDA will co-fund the project to the value of 250 KUSD (approx. 2.2 MSEK) annually for up to two years.As communicated on 17 January 2022, Inhalation Sciences submitted a formal whitepaper to the FDA’s